A 34-year-old woman with no comorbidities developed severe truncal ataxia and opsoclonus progressively over 4 days. The patient was admitted 20 days after onset of symptoms. During hospitalization, she was extensively investigated for the etiology of opsoclonus-myoclonus-ataxia syndrome (OMS). All ancillary tests performed gave normal results, including cerebrospinal fluid examination; serology for infectious diseases and collagenosis; brain and spine magnetic resonance imaging; thoracic, abdominal, and pelvic computerized tomography; and screening for gynecological neoplasias. Topiramate treatment was initiated at a starting dose of 50 mg/d and was titrated up to 150 mg/d over 10 days. During this period, the patient had a remarkable improvement of symptoms (video). After a few days, the topiramate dose was gradually decreased to 50 mg/d. However, after 1 week, ataxia and the opsoclonus clearly worsened. After reestablishing the medication dose to 150 mg/d, symptoms improved again.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Neurology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
Topiramate Effect in Opsoclonus-Myoclonus-Ataxia Syndrome
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.